Login to Your Account

Cellact inks $250M deal with Mundipharma for biliary duct cancer drug

By Nuala Moran
Staff Writer

Monday, August 14, 2017

LONDON – Cellact Pharma GmbH has sealed a $250 million plus royalties deal with Mundipharma International Ltd. for its phase II anticancer prodrug, Cap7.1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription